Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis.

Zhang, Jin; Fan, Xiongxiong; Zhang, Xiaoyu; Jiang, Fengli; Wu, Yiping; Yang, Beibei; Li, Xinghuan; Liu, Dong

Zhang, Jin; Fan, Xiongxiong; Zhang, Xiaoyu; Jiang, Fengli; Wu, Yiping; Yang, Beibei; Li, Xinghuan; Liu, Dong.

Afiliação

Zhang J; Clinical Pharmacy Office, Baoji Central Hospital, Baoji, Shaanxi, China.
Fan X; Department of Pharmacy, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China.
Zhang X; Clinical Pharmacy Office, Baoji Central Hospital, Baoji, Shaanxi, China.
Jiang F; Clinical Pharmacy Office, Baoji Central Hospital, Baoji, Shaanxi, China.
Wu Y; Clinical Pharmacy Office, Baoji Central Hospital, Baoji, Shaanxi, China.
Yang B; Clinical Pharmacy Office, Baoji Central Hospital, Baoji, Shaanxi, China.
Li X; Clinical Pharmacy Office, Baoji Central Hospital, Baoji, Shaanxi, China.
Liu D; Clinical Pharmacy Office, Baoji Central Hospital, Baoji, Shaanxi, China.

Front Pharmacol ; 14: 1293331, 2023.

Article em En | MEDLINE | ID: mdl-38074144

Palavras-chave

COVID-19; JAK-STAT inhibitors; baricitinib; efficacy and safety; immunomodulators; interleukin-6 inhibitors; tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google